Safety Evaluation of Adverse Reactions in Diabetes
(SAFEGUARD)

Research Areas

- Basic Research
- Data-Sharing Enabler
- Product Development

At a Glance

- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Location: Europe

Abstract

The primary aim of the Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD) consortium is to assess and further quantify and understand the cardio/cerebrovascular and pancreatic safety of blood glucose–lowering agents, in particular the thiazolidinediones (TZDs) and the novel incretin-based drugs and amylin analogs in Type 2 diabetes mellitus (T2DM) patients. The SAFEGUARD consortium is formed by a multidisciplinary group including diabetes experts, clinicians, pharmacologists, pharmacovigilance experts, statisticians, and pharmacoepidemiologists, and it will capitalize on knowledge generated in other European Union (EU)–funded projects to create a harmonized data platform. This platform will allow for the largest scale studies on T2DM drugs developed so far as well as for the implementation of new epidemiological studies.

Mission

The SAFEGUARD studies include the following:
Consortium History

Oct. 1, 2011: Project started
Sept. 30, 2015: Project ended

Structure & Governance

SAFEGUARD’s work is divided into the following Work Packages (WPs):
WP1 and WP2 provide scientific leadership and operational management to project research. WP3 to WP7 are the main knowledge-generating and scientific work packages, and each deals with different data substrates:

Financing

The funding scheme is through the European Union’s Seventh Framework Programme (small or medium-scale focused research project). The project cost is €3.9 million. Funding is €3.0 million.

Links/Social Media Feed

Homepage http://www.safeguard-diabetes.org/

Points of Contact

Scientific Coordinator:
Miriam Sturkenboom
Department of Medical Informatics
Erasmus University Medical Center
email: m.sturkenboom@erasmusmc.nl

Project Manager:
Mireia Manent
Synapse Research Management Partners S.L.
email: mmanent@synapse-managers.com

Contact: info@safeguard-diabetes.eu

Sponsors & Partners

Agencia Espanola de Medicamentos y Productos Sanitarios
BIPS Institut fur Epidemiologie und Praventionsforschung GmbHH
Consortio Mario Negri Sud
Drug Safety Research Trust
Erasmus Medical Center
Fondaziones Scientifica SIMG-ONLUS
PHARMO Institute N.V.
RTI Health Solutions
Stichting VU-VUMC
Synapse Research Management Partners
The Brigham and Women’s Hospital, Harvard
Medical School
Universitaet Bremen
University of Bath
University of Milano - Bicocca
Univerzita Karlova v Praze

Updated: 04/15/2016